Stocktwits on MSN
SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail
The debate centers on Sellas’ Phase 3 Regal trial, which is testing its immunotherapy Galinpepimut-S (GPS) as a maintenance ...
How could relapse in leukemia after CAR T treatment—a problem that still affects between 30–60% of patients—be prevented? One major driver is antigen escape: leukemia cells can dial down or lose the ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric ...
New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results